Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus

PHASE3RecruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetes MellitusTuberculosis
Interventions
DRUG

Isoniazid and Rifapentine (INH-RPT)

Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.

DRUG

Placebo

Participants in the control group will receive placebo once weekly for 12 weeks

Trial Locations (4)

Unknown

RECRUITING

Mbeya zonal referral hospital, Mbeya

RECRUITING

Kilimanjaro Christian Medical Center, Moshi

RECRUITING

Makerere University, Kampala

RECRUITING

Martyrs Hospital Lubaga, Kampala

All Listed Sponsors
collaborator

Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands

UNKNOWN

collaborator

Otago University, New Zealand

UNKNOWN

collaborator

Makerere University

OTHER

collaborator

St George's, University of London, United Kingdom

UNKNOWN

collaborator

Kilimanjaro Christian Medical University College (KCMUCo), Tanzania

UNKNOWN

collaborator

Uganda Martyrs Hospital Lubaga, Uganda

UNKNOWN

collaborator

King's College London

OTHER

lead

Dr. Nyanda Elias Ntinginya

OTHER_GOV

NCT04600167 - Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus | Biotech Hunter | Biotech Hunter